IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient

The IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133(+)-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a “chronic” myocardial infarction and persistent...

Descripción completa

Detalles Bibliográficos
Autores principales: Forcillo, Jessica, Stevens, Louis-Mathieu, Mansour, Samer, Prieto, Ignacio, Roy, Denis-Claude, Noiseux, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505958/
https://www.ncbi.nlm.nih.gov/pubmed/23213603
http://dx.doi.org/10.1155/2011/685394
_version_ 1782250835677282304
author Forcillo, Jessica
Stevens, Louis-Mathieu
Mansour, Samer
Prieto, Ignacio
Roy, Denis-Claude
Noiseux, Nicolas
author_facet Forcillo, Jessica
Stevens, Louis-Mathieu
Mansour, Samer
Prieto, Ignacio
Roy, Denis-Claude
Noiseux, Nicolas
author_sort Forcillo, Jessica
collection PubMed
description The IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133(+)-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a “chronic” myocardial infarction and persistent left ventricular dysfunction. Patients are followed for 2 years with different imaging techniques including the stress magnetic resonance to evaluate the global and regional myocardial viability. Before the beginning of the randomization, the 5 first patients are treated in an open-label fashion to assess safety and feasibility of the IM CD133(+) injections. Herein, we report the first Canadian patient treated with IM injection of CD133(+) cells during CABG surgery as part of the IMPACT-CABG trial.
format Online
Article
Text
id pubmed-3505958
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35059582012-12-04 IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient Forcillo, Jessica Stevens, Louis-Mathieu Mansour, Samer Prieto, Ignacio Roy, Denis-Claude Noiseux, Nicolas Case Rep Transplant Case Report The IMPACT-CABG study is the first Canadian randomized-controlled phase II clinical trial aiming to assess the effect of intramyocardial (IM) injections of CD133(+)-selected stem cells in patients referred for coronary artery bypass graft (CABG) with a “chronic” myocardial infarction and persistent left ventricular dysfunction. Patients are followed for 2 years with different imaging techniques including the stress magnetic resonance to evaluate the global and regional myocardial viability. Before the beginning of the randomization, the 5 first patients are treated in an open-label fashion to assess safety and feasibility of the IM CD133(+) injections. Herein, we report the first Canadian patient treated with IM injection of CD133(+) cells during CABG surgery as part of the IMPACT-CABG trial. Hindawi Publishing Corporation 2011 2011-06-22 /pmc/articles/PMC3505958/ /pubmed/23213603 http://dx.doi.org/10.1155/2011/685394 Text en Copyright © 2011 Jessica Forcillo et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Forcillo, Jessica
Stevens, Louis-Mathieu
Mansour, Samer
Prieto, Ignacio
Roy, Denis-Claude
Noiseux, Nicolas
IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient
title IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient
title_full IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient
title_fullStr IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient
title_full_unstemmed IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient
title_short IMPACT-CABG Trial: Implantation of CD133(+) Stem Cells in Patients Undergoing Coronary Bypass Surgery—Presentation of the First Treated Patient
title_sort impact-cabg trial: implantation of cd133(+) stem cells in patients undergoing coronary bypass surgery—presentation of the first treated patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505958/
https://www.ncbi.nlm.nih.gov/pubmed/23213603
http://dx.doi.org/10.1155/2011/685394
work_keys_str_mv AT forcillojessica impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient
AT stevenslouismathieu impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient
AT mansoursamer impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient
AT prietoignacio impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient
AT roydenisclaude impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient
AT noiseuxnicolas impactcabgtrialimplantationofcd133stemcellsinpatientsundergoingcoronarybypasssurgerypresentationofthefirsttreatedpatient

Ejemplares similares